Despite the major decline in COVID-19 vaccine sales since the 2022 peak, the infectious disease market is still expected to grow by 5.7% through 2029 with Pfizer, Gilead Sciences and GSK all set to | Despite the major decline in COVID-19 vaccine sales since the 2022 peak, the infectious disease market is still expected to grow by 5.7% through 2029 with Pfizer, Gilead and GSK all set to be the dominant forces in this market.
